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Abstract 
During tumour progression, the significant variation in the pathological deregulated pathways is 
responsible for the tumour progression of malignancy. Furthermore, the tumour microenvironment 
is highly diverse consisting of various cell types, including vascular cells. The availability of vascular 
Ŷiche is crucial for Ŷorŵal aŶd Ŷeoplastic cells. Johad FolkŵaŶ’s pioŶeer ǁork of targetiŶg the 
tuŵour ǀasculature to ͞starǀiŶg a tuŵour to death͟ ǁas coŶceiǀed ŵore thaŶ three decades ago. 
However, the approach of eradicating tumour vasculature has not been effective as we expected, 
with only extending the survival of cancer patients by few months. 
The tumorigenic mechanisms that tumour cells employ during tumour development are clearly 
dependent on pathological deregulation of the multiple pathways of host vasculature, including 
VEGF-dependent, VEGF-independent, interaction between tumour and stromal cells. Not only these 
pathways are important in the clinical perspective of their associated targeted therapeutics, but 
their studies also continue to provide critical information to the fundamental knowledge of tumour-
associated vasculature. For this reason, the present Special Issue of the Cancer Letters is dedicated 
to addressing the critical research issue of this field from the aetiology of tumour angiogenesis, the 
role of tumour vascular niche, the development of biomarkers for anti-angiogenic therapy. Topics 
and authors were careful selected to cover challenging issues within the broad field of the tumour 
microenvironment. 
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During tumour progression, the significant variation in the pathological deregulated pathways is 
responsible for the tumour progression of malignancy. Furthermore, the tumour microenvironment 
is highly diverse consisting of various cell types, including vascular cells. The availability of vascular 
Ŷiche is crucial for Ŷorŵal aŶd Ŷeoplastic cells. Johad FolkŵaŶ’s pioŶeer ǁork of targetiŶg the 
tuŵour ǀasculature to ͞starǀiŶg a tuŵour to death͟ ǁas coŶceiǀed ŵore than three decades ago. 
However, the approach of eradicating tumour vasculature has not been effective as we expected, 
with only extending the survival of cancer patients by few months. 
The tumorigenic mechanisms that tumour cells employ during tumour development are clearly 
dependent on pathological deregulation of the multiple pathways of host vasculature, including 
VEGF-dependent, VEGF-independent, interaction between tumour and stromal cells. Not only these 
pathways are important in the clinical perspective of their associated targeted therapeutics, but 
their studies also continue to provide critical information to the fundamental knowledge of tumour-
associated vasculature. For this reason, the present Special Issue of the Cancer Letters is dedicated 
to addressing the critical research issue of this field from the aetiology of tumour angiogenesis, the 
role of tumour vascular niche, the development of biomarkers for anti-angiogenic therapy. Topics 
and authors were careful selected to cover challenging issues within the broad field of the tumour 
microenvironment. 
There is a plenty of evidence that VEGF-independent angiogenic pathways are associated with 
increased anti-VEGF escape mechanisms. Some of the key factors involved in the possible 
compensatory angiogenic signalling. In this regard, Biel and Siemann review mechanisms driven by 
angiopoietin2 (Ang-2)/Tie-2 axis for vessel destabilisation and disruption of vascular endothelial cell-
cell contact, well known to be critical step for tumour angiogenesis. The authors then discuss the 
current development of the therapeutic combination by an anti-VEGF strategy with Ang-2 targeted 
agents. Lin and Jiang approach the same issue for the bone morphogenic protein (BMP) family in the 
context of solid tumour development. The authors explore the cross-talk within BMP family 
members as well as their interactions with the other angiogenic factors as an important sample for 
improvement of anti-angiogenic therapy.  
Hypoxia has been identified as a hallmark of solid tumours. It has been suggested that anti-
angiogenic agents can cause vascular collapse or regression, which may further lead to an increase in 
the hypoxia within the tumour microenvironment and selection of more aggressive clones of the 
cancer cells resisting to therapy including anti-angiogenic therapy. Broggini and colleagues 
experimentally explore targeting hypoxia for overcoming the disappointing performance of anti-
angiogenic agents in glioma. 
Tumours may progress via local invasion or/and circulation dissemination (haematogenous and 
lymphatic spread). The circulation dissemination represents a crucial developmental step in most 
tumour types as they can lead to distant metastasis. In the perspective of presenting up-to-date data 
on the poor structural integrity of the tumour-associated blood vessels related to the intravasation 
and extravasation of tumour cells, Shenoy and Lu discuss the possible mechanisms of 
transendothelial migration of cancer cells. A clear take-home message is that cancer cells can 
remodel themselves and vasculature to breach the endothelial barrier, which might lead to potential 
intervention targets for cancer metastasis. 
Worthy to note, putative associations between tumour angiogenesis and metabolic defects of the 
tumour must be evaluated in the light of current biology data. Husain and colleagues discuss the 
role of BRAF
v600E
, an oncoprotein, in the crossroad of tumour angiogenesis and cachexia in 
undifferentiated thyroid carcinoma. The authors proposed the exploitation of the mechanisms of the 
microenvironment angiogenic factors involving the metabolic defects of tumour represented a 
promising candidate for new biomarkers and therapeutic targets.  
Within the tumour microenvironment tumour and host cell populations dynamically interact via 
direct cell-to-cell contact and soluble molecules of paracrine regulation. The microenvironmental 
components are compartmentalised into different tumour niches, which harbour cancer stem cells 
(CSCs).  CSCs represent a heterogeneous subpopulation of cancer cells that retains the potential of 
self-renewal, which leads to malignant progeny. A whole new insight on how blood vascular niches 
support CSCs was achieved with studies on variety types of tumours. Three reviews in the present 
Special issue deals with the relationship between the vasculature and CSCs: Ping and colleagues 
discuss how CSCs orchestrate their vascular niches to facilitate themselves survival, maintain 
stemness and escape from radio-chemotherapy. While Jhaveri and Colleagues further suggest that 
the CSCs may sustain the vascular niches by transdifferentiating into endothelial cells directly or 
through the secretion of angiogenic factors. Colge discusses an intriguing and barely explored topic 
of targeting bone marrow vascular niches for treating the refractory acute myeloid leukaemia (AML) 
by applying anti-angiogenic agents. Mechanistic insights on how AML can functionally integrate 
within the vascular niches, become quiescence and resist cytotoxic chemotherapy. The author 
believes that there is a strong rationale to initiate a combination of anti-angiogenic agents with 
cytotoxic chemotherapy for AML treatment.  
The complexity of angiogenesis process leads to many potential targets for tumour intervention. Till 
date, more than ten anti-angiogenic agents have been approved by the US Food and Drug 
Administration (FDA) for tumour treatment. Shan and colleagues systematically review the anti-
angiogenic trials in gastric cancer. The authors found that most of the current anti-angiogenic 
settings had improved the response rate but not in overall survive compared to chemotherapy alone.   
The authors also point out that there is a lack of suitable biomarkers to select patients who may 
most benefit from the combined treatment of anti-angiogenic agents to chemotherapy, as well as of 
new biomarkers may lead to more effective anti-angiogenic therapeutic management. 
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